Information Update - Health Canada cautions against use of Sensipar in children
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Health Canada
OTTAWA, March 7, 2013 /CNW/ - Following the death of a child enrolled in
a clinical trial for the drug Sensipar in the United States, Health
Canada is reminding healthcare professionals and consumers that
Sensipar is not approved for use in patients under 18 years of age.
Sensipar (cinacalcet) is used for treating disorders of the parathyroid
gland that result in high blood calcium levels.
Amgen, the manufacturer of Sensipar, recently halted all pediatric
clinical trials of the drug after the death of a 14-year-old patient
who developed very low blood calcium levels during a trial. It has not
been determined whether Sensipar had a role in the patient's death.
There have been no clinical trials of Sensipar involving children in
As indicated in the drug label, Sensipar is not approved for use in
children. No adverse reactions to Sensipar involving a patient under 18
years of age have been reported to Health Canada. The risk of low blood
calcium levels associated with the use of Sensipar is already part of
the product labelling.
Health Canada is currently reviewing available safety information and
will consider updating the labelling information, as appropriate.
Patients with questions or concerns about their Sensipar treatment
should speak to their healthcare professional.
Additional information for healthcare professionals
The Canadian drug label for Sensipar warns about the risk of
hypocalcemia (low blood calcium levels) associated with its use.
Healthcare professionals should carefully monitor patients for this
risk. Symptoms of hypocalcemia include convulsions, irregular
heartbeat, involuntary contraction of muscles and numbness (hands,
feet, mouth, lips).